大剂量地塞米松对免疫性血小板减少性紫癜患者浆样树突状细胞功能及Toll样受体9表达的影响

王莉, 张连生, 柴晔, 等. 大剂量地塞米松对免疫性血小板减少性紫癜患者浆样树突状细胞功能及Toll样受体9表达的影响[J]. 临床血液学杂志, 2012, 25(11): 700-702,705. doi: 10.13201/j.issn.1004-2806.2012.06.006
引用本文: 王莉, 张连生, 柴晔, 等. 大剂量地塞米松对免疫性血小板减少性紫癜患者浆样树突状细胞功能及Toll样受体9表达的影响[J]. 临床血液学杂志, 2012, 25(11): 700-702,705. doi: 10.13201/j.issn.1004-2806.2012.06.006
WANG Li, ZHANG Liansheng, CHAI Ye, et al. Effect of high-dose dexamethasone on the function and TLR-9 expression of plasmacytoid dendritic cells in patients with immune thrombocytopenic purpura[J]. J Clin Hematol, 2012, 25(11): 700-702,705. doi: 10.13201/j.issn.1004-2806.2012.06.006
Citation: WANG Li, ZHANG Liansheng, CHAI Ye, et al. Effect of high-dose dexamethasone on the function and TLR-9 expression of plasmacytoid dendritic cells in patients with immune thrombocytopenic purpura[J]. J Clin Hematol, 2012, 25(11): 700-702,705. doi: 10.13201/j.issn.1004-2806.2012.06.006

大剂量地塞米松对免疫性血小板减少性紫癜患者浆样树突状细胞功能及Toll样受体9表达的影响

详细信息
    通讯作者: 张连生,E-mail:zls2170@yahoo.com
  • 中图分类号: R554

Effect of high-dose dexamethasone on the function and TLR-9 expression of plasmacytoid dendritic cells in patients with immune thrombocytopenic purpura

More Information
  • 目的:研究大剂量地塞米松对免疫性血小板减少性紫癜(ITP)患者浆样树突状细胞(pDCs)功能及Toll样受体9表达的影响。方法:15例初诊的ITP患者给予地塞米松40 mg/d,连用4 d。采用免疫磁珠分离法体外分离15例正常对照及13例治疗有效患者治疗前后外周血中浆细胞样树突状细胞(pDCs),用CPG-ODN 2216刺激外周血pDCs并与之共培养24 h,采用酶标记免疫吸附(ELISA)方法检测上清中IFN-α、IL-6、TNF-α的含量;实时定量聚合酶链反应(RT-PCR)检测pDCs的TLR9 mRNA表达量。结果:①治疗前pDCs产生IFN-α、IL-6、TNF-α细胞因子的水平[(960.83±164.65)pg/ml,(156.15±39.89)pg/ml,(137.31±35.44)pg/ml]明显高于正常对照组[(616.67±105.98)pg/ml,(89.13±21.48)pg/ml,(88.53±25.81)pg/ml)](P<0.05);治疗后pDCs产生IFN-α、IL-6、TNF-α细胞因子水平分别降至(678.46±128.88)pg/ml、(97.77±26.31)pg/ml、(103.08±26.42)pg/ml,与治疗前比较差异有统计学意(P<0.05),与正常对照组比较,差异无统计学意义(P>0.05)。②治疗前pDCs的TLR9 mRNA的表达水平高于正常对照组(P<0.05);治疗后pDCs的TLR9 mRNA的表达水平低于治疗前(P<0.05),但与正常对照组的表达水平比较,差异无统计学意义(P>0.05)。结论:pDCs分泌的细胞因子及其表达的TLR9在ITP发病中起重要作用;地塞米松可能通过下调TLR9的表达,抑制pDCs分泌细胞因子的功能,从而对ITP起到治疗作用。
  • 加载中
  • [1]

    ROBAK E,SYSA-JEDRZEJOWSKA A,ROBAK T,et al.Peripheral blood lymphocyte apoptosis and circulating dendritic cells in patients with systemic lupus erythematosus correlation with immunological status and disease-related symptom[J].Clin Rheumatol,2006,25:225-233.

    [2]

    PATOLE P S,PAWAR R D,LECH M,et al.Expression and regulation of Toll-like receptors in lupus-like immune complex glomerulonephritis of MRL-Fas(lpr)mice[J].Nephrol Dial Transplant,2006,21:3062-3073.

    [3]

    陈静,谭志建,刘厚军,等.浆细胞样树突状细胞和TLR9及其mRNA在银屑病患者皮损中的表达[J].中国麻风皮肤病杂志,2007,23(6):459-461.

    [4]

    KIYOSHI T,SHIZUO A.Toll-like receptors in innate immunity[J].Int Immunol,2005,17:1-14.

    [5]

    中华医学会血液学会血栓与止血学组.成人原发免疫性血小板减少症诊治的中国专家共识(修订版)[J].中华血液学杂志,2011,32(3):214-216.

    [6]

    MEGJUGORAC N,YOUNG H A,AMRUTE S B,et al.Virally stimulated plasmacytoid dendritic cells produce chemokines and induce migration of T and NK cells[J].J Leukoc Biol,2004,75:504-514.

    [7]

    KNUEFERMANN P,SCHWEDERSKI M,VELTEN M,et al.Bacterial DNA induces myocardial inflammation and reduces cardiomyocyte contractility:role of toll-like receptor 9[J].Cardiovasc Res,2008,78:26-35.

    [8]

    SUMMERS K L,MARLEAU A M,MAHON J L,et al.Reduced IFN-α secretion by blood dendritic cells in human diabetes[J].Clin Immunol,2006,121:81-89.

    [9]

    STASI R,EVANGELISTA M L,STIPA E,et al.Idiopathic thrombocytopenic purpura:current concepts in pathophysiology and management[J].Thromb Haemost,2008,99:4-13.

    [10]

    CHENG Y,WONG R S,SOO Y O,et al.Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone[J].N Engl J Med,2003,349:831-836.

    [11]

    MAZZUCCONI M G,FAZI P,BERNASCONI S,et al.Therapy with high-dose dexamethasone(HD-DXM)in previously untreated patients affected by idiopathic thrombocytopenic purpura:a GIMEMA experience[J].Blood,2007,109:1401-1407.

  • 加载中
计量
  • 文章访问数:  402
  • PDF下载数:  422
  • 施引文献:  0
出版历程
收稿日期:  2012-02-09

目录